This company seems to have been delisted
Reason: Acquired by Kyowa Kirin
Last recorded trade on: March 20, 2024
Source: https://www.ns-healthcare.com/news/kyowa-kirin-wraps-up-acquisition-of-orchard-therapeutics/
Reason: Acquired by Kyowa Kirin
Last recorded trade on: March 20, 2024
Source: https://www.ns-healthcare.com/news/kyowa-kirin-wraps-up-acquisition-of-orchard-therapeutics/
Orchard Therapeutics
ORTX
S$21.25
Share price
0.00%
Change (1 day)
223.37%
Change (1 year)
Orchard Therapeutics (ORTX) - Total liabilities
Total liabilities on the balance sheet as of September 2023 : S$0.15 Billion
According to Orchard Therapeutics 's latest financial reports the company's total liabilities are S$0.15 Billion. A company’s total liabilities is the sum of all current and non-current debts and obligations.
Orchard Therapeutics - Total liabilities on balance sheet (from 2017 to 2023)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2022-12-31 | S$0.16 B | 6.38% |
| 2021-12-31 | S$0.15 B | 12.12% |
| 2020-12-31 | S$0.13 B | 0.5% |
| 2019-12-31 | S$0.13 B | 80.56% |
| 2018-12-31 | S$74.73 M | 413.14% |
| 2017-12-31 | S$14.56 M | -51.64% |
| 2016-12-31 | S$30.11 M |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 Novocure
NVCR | S$1.12 B | 626.88% | Jersey |
 Novavax NVAX | S$1.74 B | 1,021.76% | 🇺🇸 USA |
 Organovo ONVO | S$5.28 M | -96.59% | 🇺🇸 USA |
 Orchard Therapeutics
ORTX | S$0.15 B | 0.00% | 🇬🇧 UK |